MCID: MYL006
MIFTS: 61

Myeloid Leukemia

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Myeloid Leukemia

MalaCards integrated aliases for Myeloid Leukemia:

Name: Myeloid Leukemia 12 20 29 54 15 71
Myeloid Leukaemia 12 32
Myeloid Granulocytic Leukaemia 12
Myeloid Granulocytic Leukemia 12
Non-Lymphocytic Leukemia 12
Leukaemia Myelogenous 12
Leukemia Myelogenous 12
Leukemia, Myeloid 74

Classifications:



External Ids:

Disease Ontology 12 DOID:8692
ICD9CM 34 205
MeSH 44 D007951
NCIt 50 C3172
SNOMED-CT 67 269631008
ICD10 32 C92 C92.9
UMLS 71 C0023470

Summaries for Myeloid Leukemia

Disease Ontology : 12 A leukemia that is located in myeloid tissue.

MalaCards based summary : Myeloid Leukemia, also known as myeloid leukaemia, is related to leukemia, chronic myeloid and leukemia, acute myeloid. An important gene associated with Myeloid Leukemia is MIR99AHG (Mir-99a-Let-7c Cluster Host Gene), and among its related pathways/superpathways are Pathways in cancer and Endometrial cancer. The drugs Nicotine and Daunorubicin have been mentioned in the context of this disorder. Affiliated tissues include myeloid tissue, myeloid and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Myeloid leukemia is a type of leukemia affecting myeloid... more...

Related Diseases for Myeloid Leukemia

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34) Acute Myeloid Leukemia with T(9;22)(q34.1;q11.2)

Diseases related to Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1351)
# Related Disease Score Top Affiliating Genes
1 leukemia, chronic myeloid 33.7 U2AF1 RUNX1 RARA PTPN11 MCL1 KIT
2 leukemia, acute myeloid 33.7 U2AF1 RUNX1T1 RUNX1 RARA PTPN11 NPM1
3 core binding factor acute myeloid leukemia 33.5 RUNX1 KIT FLT3 CEBPA CBFB
4 cytogenetically normal acute myeloid leukemia 33.4 NPM1 FLT3 CEBPA
5 atypical chronic myeloid leukemia 33.4 U2AF1 RUNX1 FLT3 ETV6 ABL1
6 acute promyelocytic leukemia 33.3 RUNX1T1 RUNX1 RARA NPM1 FLT3 ETV6
7 acute myeloblastic leukemia with maturation 33.2 NPM1 KIT FLT3
8 childhood acute myeloid leukemia 33.1 NPM1 KIT FLT3
9 leukemia 33.1 U2AF1 RUNX1T1 RUNX1 RARA PTPN11 NPM1
10 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 33.1 RUNX1 MYH11 KIT FLT3 ETV6 CBFB
11 myelodysplastic syndrome 33.0 U2AF1 RUNX1 PTPN11 NPM1 MLF1 MCL1
12 cebpa-associated familial acute myeloid leukemia 32.8 RUNX1 NPM1 KIT GATA2 FLT3 ETV6
13 myeloid sarcoma 32.7 U2AF1 NPM1 KIT FLT3
14 essential thrombocythemia 32.6 U2AF1 PTPN11 KIT ABL1
15 acute myeloblastic leukemia without maturation 32.6 NPM1 FLT3
16 monocytic leukemia 32.6 RUNX1 RARA FLT3
17 acute myeloid leukemia with t(8;21)(q22;q22) translocation 32.5 RUNX1T1 RUNX1 KIT FLT3 CEBPA
18 childhood leukemia 32.5 RUNX1 PTPN11 ETV6 ABL1
19 polycythemia vera 32.5 U2AF1 KIT ETV6 ABL1
20 leukemia, acute monocytic 32.4 U2AF1 RARA FLT3
21 acute leukemia 32.4 RUNX1T1 RUNX1 RARA NPM1 KIT HOXA9
22 myelodysplastic/myeloproliferative neoplasm 32.4 U2AF1 PTPN11 KIT FLT3 ETV6 ABL1
23 juvenile myelomonocytic leukemia 32.3 U2AF1 RUNX1 RARA PTPN11 FLT3 ETV6
24 myeloproliferative neoplasm 32.2 U2AF1 RUNX1 PTPN11 KIT FLT3 ETV6
25 leukemia, acute lymphoblastic 32.2 U2AF1 RUNX1 PTPN11 MCL1 KIT HOXA9
26 thrombocytopenia 32.0 U2AF1 RUNX1 PTPN11 NPM1 KIT GATA2
27 myelofibrosis 32.0 U2AF1 RUNX1 NPM1 KIT GATA2 FLT3
28 acute megakaryocytic leukemia 31.9 U2AF1 RUNX1T1 RUNX1 RARA MYH11 MIR99AHG
29 chronic myelomonocytic leukemia 31.8 U2AF1 RUNX1 PTPN11 NPM1 KIT HOXA9
30 wilms tumor 1 31.8 U2AF1 NPM1 FLT3 CEBPA ABL1
31 myeloma, multiple 31.7 U2AF1 PTPN11 MCL1 KIT FLT3
32 leukemia, chronic lymphocytic 31.7 U2AF1 PTPN11 MCL1 FLT3 ABL1
33 chronic leukemia 31.5 U2AF1 KIT FLT3 ABL1
34 lymphoma, non-hodgkin, familial 31.5 U2AF1 NPM1 MCL1 FLT3 ETV6
35 b-lymphoblastic leukemia/lymphoma 31.5 PTPN11 KIT FLT3 ETV6 ABL1
36 precursor t-cell acute lymphoblastic leukemia 31.5 FLT3 ETV6 ABL1
37 hematologic cancer 31.4 U2AF1 RUNX1T1 RUNX1 RARA PTPN11 NPM1
38 t-cell acute lymphoblastic leukemia 31.4 U2AF1 RUNX1 FLT3 ETV6 ABL1
39 blood platelet disease 31.4 U2AF1 RUNX1 KIT FLT3 ABL1
40 gastrointestinal stromal tumor 31.3 MYH11 MCL1 KIT FLT3 ABL1
41 severe congenital neutropenia 31.3 U2AF1 RUNX1 PTPN11 FLT3
42 childhood acute lymphocytic leukemia 31.1 U2AF1 RUNX1 PTPN11 MCL1 FLT3 ETV6
43 refractory cytopenia with multilineage dysplasia 31.1 U2AF1 GATA2
44 aleukemic leukemia cutis 30.9 RARA NPM1
45 chronic eosinophilic leukemia 30.9 U2AF1 KIT FLT3 ETV6 ABL1
46 8p11 myeloproliferative syndrome 30.8 RUNX1 KIT FLT3
47 aggressive systemic mastocytosis 30.8 U2AF1 RUNX1 PTPN11 KIT FLT3
48 bone marrow cancer 30.7 U2AF1 NPM1 MCL1 KIT FLT3 ABL1
49 sm-ahnmd 30.7 U2AF1 KIT
50 partial deletion of the long arm of chromosome 16 30.6 MYH11 CBFB

Graphical network of the top 20 diseases related to Myeloid Leukemia:



Diseases related to Myeloid Leukemia

Symptoms & Phenotypes for Myeloid Leukemia

GenomeRNAi Phenotypes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

26 (show top 50) (show all 52)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 10.39 FLT3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 10.39 RARA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-118 10.39 PTPN11
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 10.39 FLT3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-121 10.39 CEBPA FLT3 PTPN11
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 10.39 CEBPA FLT3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 10.39 FLT3
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-138 10.39 PTPN11
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.39 CEBPA FLT3
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.39 CEBPA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-149 10.39 PTPN11
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.39 RARA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-163 10.39 FLT3
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 10.39 FLT3
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.39 FLT3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.39 PTPN11
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.39 CEBPA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-37 10.39 PTPN11 RARA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 10.39 CEBPA
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-47 10.39 PTPN11
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 10.39 RARA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 10.39 CEBPA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.8 U2AF1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.8 U2AF1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.8 ABL1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.8 KIT
27 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.8 U2AF1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.8 ABL1 KIT
29 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.8 KIT
30 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.8 CBFB
31 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.8 U2AF1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.8 ABL1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.8 ABL1 KIT
34 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.8 ABL1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.8 CBFB
36 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.8 ABL1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.8 ABL1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-48 9.8 CEBPA
39 Increased shRNA abundance (Z-score > 2) GR00366-A-55 9.8 CBFB
40 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.8 KIT
41 Increased shRNA abundance (Z-score > 2) GR00366-A-72 9.8 CEBPA
42 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.8 CBFB
43 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.8 ABL1 KIT U2AF1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.8 CBFB
45 Increased shRNA abundance (Z-score > 2) GR00366-A-89 9.8 U2AF1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.8 KIT
47 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.8 U2AF1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.8 KIT
49 Decreased substrate adherent cell growth GR00193-A-1 9.63 KIT
50 Decreased substrate adherent cell growth GR00193-A-2 9.63 ABL1 KIT

MGI Mouse Phenotypes related to Myeloid Leukemia:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 ABL1 CBFB CEBPA ERG ETV6 FLT3
2 cardiovascular system MP:0005385 10.4 ABL1 CBFB CEBPA ERG ETV6 GATA2
3 hematopoietic system MP:0005397 10.38 ABL1 CBFB CEBPA ERG ETV6 FLT3
4 growth/size/body region MP:0005378 10.37 ABL1 CBFB CEBPA ERG ETV6 FLT3
5 endocrine/exocrine gland MP:0005379 10.36 ABL1 CBFB CEBPA ERG ETV6 FLT3
6 immune system MP:0005387 10.33 ABL1 CBFB CEBPA ERG ETV6 FLT3
7 embryo MP:0005380 10.26 ABL1 CBFB ERG ETV6 GATA2 KIT
8 mortality/aging MP:0010768 10.24 ABL1 CBFB CEBPA ERG ETV6 FLT3
9 integument MP:0010771 10.21 CBFB CEBPA ERG ETV6 HOXA9 KIT
10 digestive/alimentary MP:0005381 10.19 ABL1 CBFB CEBPA ETV6 KIT MYH11
11 liver/biliary system MP:0005370 10.1 ABL1 CBFB CEBPA ETV6 GATA2 KIT
12 neoplasm MP:0002006 10.02 CBFB CEBPA ERG ETV6 FLT3 KIT
13 normal MP:0002873 9.93 ABL1 CBFB CEBPA ERG ETV6 GATA2
14 no phenotypic analysis MP:0003012 9.8 CBFB CEBPA ETV6 FLT3 KIT PTPN11
15 reproductive system MP:0005389 9.61 CEBPA ERG GATA2 HOXA9 KIT MCL1
16 respiratory system MP:0005388 9.28 ABL1 CBFB CEBPA ERG KIT MYH11

Drugs & Therapeutics for Myeloid Leukemia

Drugs for Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 543)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Daunorubicin Approved Phase 4 20830-81-3 30323
3
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
4
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
5
Lenalidomide Approved Phase 4 191732-72-6 216326
6 HH-GV-678 Phase 4
7 Aclacinomycins Phase 4
8 Tin Fluorides Phase 4
9 Imatinib Mesylate Phase 4 220127-57-1 123596
10 Angiogenesis Inhibitors Phase 4
11
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
12
Lorazepam Approved Phase 3 846-49-1 3958
13
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
14
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
15
Thioguanine Approved Phase 3 154-42-7 2723601
16
Mercaptopurine Approved Phase 3 50-44-2 667490
17
Adenosine Approved, Investigational Phase 3 58-61-7 60961
18 Orange Approved Phase 2, Phase 3
19
Isavuconazole Approved, Investigational Phase 2, Phase 3 241479-67-4
20
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
21
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
22
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
23
Enalaprilat Approved Phase 3 76420-72-9 6917719
24
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
25
Ofloxacin Approved Phase 3 82419-36-1 4583
26
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
27
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
28
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
29
Panobinostat Approved, Investigational Phase 3 404950-80-7 6918837
30
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
31
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
32
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
33
Morphine Approved, Investigational Phase 3 57-27-2 5288826
34
Iodine Approved, Investigational Phase 3 7553-56-2 807
35
Captopril Approved Phase 3 62571-86-2 44093
36
Atorvastatin Approved Phase 3 134523-00-5 60823
37
Nalbuphine Approved Phase 3 20594-83-6 5360630 5311304
38
Abatacept Approved Phase 3 332348-12-6 10237
39
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
40
tannic acid Approved Phase 3 1401-55-4
41
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
42
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
43
Venetoclax Approved, Investigational Phase 3 1257044-40-8 49846579
44
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
45
midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
46
Peginterferon alfa-2b Approved Phase 2, Phase 3 215647-85-1, 99210-65-8
47
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
48
Mycophenolic acid Approved Phase 3 24280-93-1 446541
49
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
50
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755

Interventional clinical trials:

(show top 50) (show all 2834)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
3 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Unknown status NCT03216070 Phase 4 Dasatinib 50 MG
4 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
5 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
6 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
7 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Unknown status NCT02926586 Phase 4 Fludarabine;Cytarabine
8 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Unknown status NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
9 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
10 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
11 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
12 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
13 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
14 Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
15 A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
16 An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial Completed NCT01368523 Phase 4 nilotinib
17 A PHASE 4 SAFETY AND EFFICACY STUDY OF BOSUTINIB (BOSULIF (REGISTERED)) IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA PREVIOUSLY TREATED WITH ONE OR MORE TYROSINE KINASE INHIBITORS Completed NCT02228382 Phase 4 Bosutinib
18 An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
19 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
20 A Phase 4 Study of Nilotinib in Korean Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase Completed NCT03332511 Phase 4 Nilotinib
21 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
22 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. Completed NCT00180115 Phase 4 Cytarabine Dosage
23 AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
24 FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
25 A Multi-center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
26 Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
27 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
28 Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV) Completed NCT01578213 Phase 4 Imatinib mesylate
29 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
30 A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib Completed NCT01043874 Phase 4 Nilotinib
31 CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy Completed NCT01243489 Phase 4
32 A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed NCT01227577 Phase 4 Nilotinib
33 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML Completed NCT00171899 Phase 4 imatinib mesylate
34 An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
35 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
36 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
37 Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis Completed NCT02875743 Phase 4 Posaconazole
38 PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
39 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
40 FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia. Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
41 A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia Completed NCT02267993 Phase 4 recombinant human thrombopoietin
42 Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
43 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415 Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
44 Efficacy and Safety of Dasatinib 70 mg as First-Line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Recruiting NCT04155411 Phase 4 Dasatinib
45 The Feasibility of Safely Managing Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment Recruiting NCT03988205 Phase 4 CPX-351
46 The Efficacy and Safety of Azacytidine Combined With HAG Regimen Versus Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy: a Prospective, Randomized Controlled Trial Recruiting NCT03873311 Phase 4 Azacytidine, HAG Regimen;Azacytidine
47 A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG (TRADEMARKER)) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA Recruiting NCT03727750 Phase 4 Gemtuzumab Ozogamicin
48 Efficacy and the Safety of Flumatinib in Treatment of CML-CP Patients With Ph+ Post Imatinib Failure Recruiting NCT04677439 Phase 4 Flumatinib
49 A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID Active, not recruiting NCT02546674 Phase 4 Nilotinib
50 A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine

Search NIH Clinical Center for Myeloid Leukemia

Inferred drug relations via UMLS 71 / NDF-RT 51 :


dasatinib
imatinib
ponatinib

Genetic Tests for Myeloid Leukemia

Genetic tests related to Myeloid Leukemia:

# Genetic test Affiliating Genes
1 Myeloid Leukemia 29

Anatomical Context for Myeloid Leukemia

The Foundational Model of Anatomy Ontology organs/tissues related to Myeloid Leukemia:

19
Myeloid Tissue

MalaCards organs/tissues related to Myeloid Leukemia:

40
Myeloid, Bone Marrow, T Cells, Bone, Nk Cells, Endothelial, Breast

Publications for Myeloid Leukemia

Articles related to Myeloid Leukemia:

(show top 50) (show all 37942)
# Title Authors PMID Year
1
Acetylation of lysine 564 adjacent to the C-terminal binding protein-binding motif in EVI1 is crucial for transcriptional activation of GATA2. 54 61
20363750 2010
2
Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature. 54 61
20445327 2010
3
Loss of CAK phosphorylation of RAR{alpha} mediates transcriptional control of retinoid-induced cancer cell differentiation. 54 61
19917671 2010
4
A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. 54 61
19880492 2010
5
Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia. 54 61
19935430 2010
6
Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines. 54 61
20084277 2010
7
Transforming growth-interacting factor (TGIF) regulates proliferation and differentiation of human myeloid leukemia cells. 54 61
19699159 2009
8
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. 54 61
19734451 2009
9
[Supportive therapies for myeloid leukemia including blood transfusion and growth factors]. 61 54
19860196 2009
10
Decreased TLR4 gene expression in leukemic leukocyte populations. 61 54
19631641 2009
11
c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D. 61 54
19339050 2009
12
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. 54 61
19407318 2009
13
Retraction notice to "The retinoic acid receptor/CaMKII interaction: pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells" [Blood Cells Mol. Dis. 39 (2007) 307-315]. 54 61
19388154 2009
14
[Apoptosis of human myeloid leukemia cell line HL-60 cells induced by siRNA targeting gene c-myc]. 61 54
19379561 2009
15
[Abnormal expression of transcription factors LYL1 and LMO2 and interaction between them in myeloid leukemia]. 61 54
19671288 2009
16
Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. 61 54
19429444 2009
17
Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. 54 61
19058874 2009
18
CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis. 61 54
19960054 2009
19
AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation. 61 54
18687517 2008
20
PR1 vaccination in myeloid malignancies. 61 54
18767937 2008
21
DMNQ-S17 inhibits constitutive NF-kappaB activation leading to induction of apoptosis through the activation of caspase-3 in human myeloid leukemia U937 cells. 61 54
18718843 2008
22
Expression profile of CREB knockdown in myeloid leukemia cells. 54 61
18801183 2008
23
Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. 61 54
18059480 2008
24
[Dihydroartemisinin down-regulates the expression of transferrin receptor in myeloid leukemia cells]. 54 61
18822958 2008
25
Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion. 54 61
18569848 2008
26
Genomic structure, alternative splicing and expression of TG-interacting factor, in human myeloid leukemia blasts and cell lines. 61 54
18455519 2008
27
TLS-ERG leukemia fusion protein deregulates cyclin-dependent kinase 1 and blocks terminal differentiation of myeloid progenitor cells. 54 61
18505930 2008
28
TGFbeta-mediated formation of pRb-E2F complexes in human myeloid leukemia cells. 54 61
18294958 2008
29
Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. 61 54
18483256 2008
30
Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling. 54 61
18414055 2008
31
Development of Notch-dependent T-cell leukemia by deregulated Rap1 signaling. 61 54
18180377 2008
32
Ezrin is a target for oncogenic Kit mutants in murine erythroleukemia. 61 54
18182570 2008
33
Targeted drug delivery via folate receptors. 61 54
18318652 2008
34
CREB is a critical regulator of normal hematopoiesis and leukemogenesis. 61 54
17975014 2008
35
[Expression and effect of neuropilin-1 in acute myeloid leukemic cells]. 61 54
18088455 2007
36
[Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell]. 54 61
18476539 2007
37
Increased responsiveness to TLR2 and TLR4 ligands during dimethylsulfoxide-induced neutrophil-like differentiation of HL-60 myeloid leukemia cells. 54 61
17664007 2007
38
The retinoic acid receptor/CaMKII interaction: pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells. 61 54
17644368 2007
39
Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. 54 61
17917967 2007
40
Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. 54 61
17081606 2007
41
Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. 54 61
17644747 2007
42
Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. 61 54
17409267 2007
43
Evidence that the Pim1 kinase gene is a direct target of HOXA9. 54 61
17327400 2007
44
Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway. 61 54
17583492 2007
45
CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells. 54 61
17431504 2007
46
Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis. 61 54
17381798 2007
47
Quantitative high-resolution CpG island mapping with Pyrosequencing reveals disease-specific methylation patterns of the CDKN2B gene in myelodysplastic syndrome and myeloid leukemia. 54 61
17095538 2007
48
Re: Henschler R, Brennscheidt U, Mertelsmann R, and Herrmann F (1991). Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine. 54 61
17213995 2007
49
Identification of novel nuclear localization signals of Drosophila myeloid leukemia factor. 54 61
18159124 2007
50
Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities. 54 61
17604209 2007

Variations for Myeloid Leukemia

Expression for Myeloid Leukemia

Search GEO for disease gene expression data for Myeloid Leukemia.

Pathways for Myeloid Leukemia

GO Terms for Myeloid Leukemia

Cellular components related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.93 U2AF1 RUNX1T1 RUNX1 RARA PTPN11 NPM1
2 chromatin GO:0000785 9.8 RUNX1 RARA HOXA9 GATA2 ETV6 ERG
3 nucleus GO:0005634 9.53 U2AF1 RUNX1T1 RUNX1 RARA PTPN11 NPM1
4 core-binding factor complex GO:0016513 8.96 RUNX1 CBFB

Biological processes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.09 RUNX1 NPM1 KIT HOXA9 GATA2 ETV6
2 multicellular organism development GO:0007275 10.08 MLF1 MCL1 KIT HOXA9 FLT3 ERG
3 negative regulation of transcription by RNA polymerase II GO:0000122 10.06 RUNX1 RARA GATA2 ETV6 CEBPA CBFB
4 cell differentiation GO:0030154 10.05 RARA MLF1 MCL1 GATA2 FLT3 ETV6
5 protein phosphorylation GO:0006468 10.04 RARA KIT FLT3 ERG ABL1
6 regulation of transcription, DNA-templated GO:0006355 10.02 RUNX1 RARA MLF1 HOXA9 GATA2 ETV6
7 regulation of apoptotic process GO:0042981 9.9 RARA MCL1 FLT3 ABL1
8 cytokine-mediated signaling pathway GO:0019221 9.85 PTPN11 MCL1 KIT FLT3 CEBPA
9 transcription, DNA-templated GO:0006351 9.82 RUNX1T1 MLF1 HOXA9
10 male gonad development GO:0008584 9.81 RARA KIT HOXA9
11 interleukin-6-mediated signaling pathway GO:0070102 9.65 PTPN11 CEBPA
12 cell fate determination GO:0001709 9.65 MCL1 GATA2
13 cell maturation GO:0048469 9.65 GATA2 CEBPA CBFB
14 regulation of keratinocyte differentiation GO:0045616 9.63 RUNX1 CBFB
15 regulation of regulatory T cell differentiation GO:0045589 9.63 RUNX1 CBFB
16 megakaryocyte development GO:0035855 9.62 PTPN11 KIT
17 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.62 RUNX1 CBFB
18 regulation of hematopoietic stem cell differentiation GO:1902036 9.62 RUNX1 GATA2 CBFB ABL1
19 hematopoietic stem cell proliferation GO:0071425 9.61 RUNX1 ETV6
20 regulation of bicellular tight junction assembly GO:2000810 9.61 RUNX1 CBFB
21 regulation of myeloid cell differentiation GO:0045637 9.59 RUNX1 CBFB
22 regulation of response to DNA damage stimulus GO:2001020 9.58 MCL1 ABL1
23 myeloid cell differentiation GO:0030099 9.58 RUNX1 CEBPA CBFB
24 regulation of B cell receptor signaling pathway GO:0050855 9.57 RUNX1 CBFB
25 Bergmann glial cell differentiation GO:0060020 9.56 PTPN11 ABL1
26 hemopoiesis GO:0030097 9.56 RUNX1 KIT GATA2 FLT3
27 regulation of cytokine-mediated signaling pathway GO:0001959 9.55 RUNX1 CBFB
28 positive regulation of CD8-positive, alpha-beta T cell differentiation GO:0043378 9.52 RUNX1 CBFB
29 negative regulation of CD4-positive, alpha-beta T cell differentiation GO:0043371 9.49 RUNX1 CBFB
30 definitive hemopoiesis GO:0060216 9.33 HOXA9 GATA2 CBFB
31 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 RUNX1 RARA NPM1 HOXA9 GATA2 ETV6
32 myeloid progenitor cell differentiation GO:0002318 9.13 MLF1 KIT FLT3

Molecular functions related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 10 RUNX1 RARA HOXA9 GATA2 ETV6 ERG
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.95 RUNX1 RARA HOXA9 GATA2 ETV6 ERG
3 sequence-specific double-stranded DNA binding GO:1990837 9.88 RARA HOXA9 GATA2 ERG ABL1
4 chromatin binding GO:0003682 9.83 RARA NPM1 GATA2 ERG CEBPA
5 transcription factor binding GO:0008134 9.77 RUNX1 RARA NPM1 GATA2 CEBPA
6 sequence-specific DNA binding GO:0043565 9.73 RARA GATA2 ETV6 ERG CEBPA CBFB
7 protein domain specific binding GO:0019904 9.72 RARA PTPN11 MLF1 ETV6 ABL1
8 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.63 RUNX1 HOXA9 GATA2 ETV6 ERG CEBPA
9 DNA-binding transcription factor activity GO:0003700 9.5 RUNX1 RARA HOXA9 GATA2 ETV6 ERG
10 DNA binding GO:0003677 9.36 RUNX1T1 RUNX1 RARA MLF1 HOXA9 GATA2

Sources for Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....